<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "journalpublishing3.dtd">
<article xml:lang="en" article-type="research-article" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<?release-delay 0|0?>
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">ETM</journal-id>
<journal-title-group>
<journal-title>Experimental and Therapeutic Medicine</journal-title>
</journal-title-group>
<issn pub-type="ppub">1792-0981</issn>
<issn pub-type="epub">1792-1015</issn>
<publisher>
<publisher-name>D.A. Spandidos</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="publisher-id">ETM-23-5-11288</article-id>
<article-id pub-id-type="doi">10.3892/etm.2022.11288</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Articles</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Balanitis xerotica obliterans: An observational, descriptive and retrospective clinical study</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Fekete</surname><given-names>Gyula L&#x00E1;szl&#x00F3;</given-names></name>
<xref rid="af1-ETM-23-5-11288" ref-type="aff">1</xref>
<xref rid="af2-ETM-23-5-11288" ref-type="aff">2</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Schwarzkopf-Kolb</surname><given-names>Dominik</given-names></name>
<xref rid="af1-ETM-23-5-11288" ref-type="aff">1</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name><surname>Brihan</surname><given-names>Ilarie</given-names></name>
<xref rid="af3-ETM-23-5-11288" ref-type="aff">3</xref>
<xref rid="c1-ETM-23-5-11288" ref-type="corresp"/>
</contrib>
<contrib contrib-type="author">
<name><surname>Boda</surname><given-names>Daniel</given-names></name>
<xref rid="af4-ETM-23-5-11288" ref-type="aff">4</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Fekete</surname><given-names>L&#x00E1;szl&#x00F3;</given-names></name>
<xref rid="af2-ETM-23-5-11288" ref-type="aff">2</xref>
<xref rid="af5-ETM-23-5-11288" ref-type="aff">5</xref>
</contrib>
</contrib-group>
<aff id="af1-ETM-23-5-11288"><label>1</label>Department of Dermatology, &#x2018;George Emil Palade&#x2019; University of Medicine, Pharmacy, Science and Technology, 540142 T&#x00E2;rgu Mure&#x0219;, Romania</aff>
<aff id="af2-ETM-23-5-11288"><label>2</label>CMI DERMAMED Private Medical Office, 540530 T&#x00E2;rgu Mure&#x0219;, Romania</aff>
<aff id="af3-ETM-23-5-11288"><label>3</label>Department of Dermatology, Dermatology Clinic, Faculty of Medicine and Pharmacy, University of Oradea, 410073 Oradea, Romania</aff>
<aff id="af4-ETM-23-5-11288"><label>4</label>Dermatology Research Laboratory, &#x2018;Carol Davila&#x2019; University of Medicine and Pharmacy, 050474 Bucharest, Romania</aff>
<aff id="af5-ETM-23-5-11288"><label>5</label>Department of Dermatology, Mure&#x0219; County Hospital, 540116 T&#x00E2;rgu Mure&#x0219;, Romania</aff>
<author-notes>
<corresp id="c1-ETM-23-5-11288"><italic>Correspondence to:</italic> Dr Ilarie Brihan, Department of Dermatology, Dermatology Clinic, Faculty of Medicine and Pharmacy, University of Oradea, 10 Pia&#x021B;a 1 Decembrie, 410073 Oradea, Romania <email>dermafek@yahoo.com</email></corresp>
<fn><p>Dr Daniel Boda, Dermatology Research Laboratory, &#x2018;Carol Davila&#x2019; University of Medicine and Pharmacy, 8 Eroii Sanitari Boulevard, 050474 Bucharest, Romania <email>lacifek@yahoo.com</email></p></fn>
</author-notes>
<pub-date pub-type="ppub">
<month>05</month>
<year>2022</year></pub-date>
<pub-date pub-type="epub">
<day>31</day>
<month>03</month>
<year>2022</year></pub-date>
<volume>23</volume>
<issue>5</issue>
<elocation-id>361</elocation-id>
<history>
<date date-type="received">
<day>28</day>
<month>01</month>
<year>2022</year>
</date>
<date date-type="accepted">
<day>15</day>
<month>03</month>
<year>2022</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#x00A9; 2020, Spandidos Publications</copyright-statement>
<copyright-year>2020</copyright-year>
</permissions>
<abstract>
<p>Lichen sclerosus is a chronic disease of unknown etiology that can occur in the genital area of both sexes. Balanitis xerotica obliterans (BXO) occurs only in the genital area of men and typically affects the foreskin, penile glans, and/or the meatus. In the present report, an observational, descriptive, and retrospective epidemiological clinical study of available data between January 2006 and December 2020 in patients diagnosed with BXO from the casuistic of CMI DERMAMED (T&#x00E2;rgu Mure&#x0219;, Romania) was performed. During this 15-year period, 164 patients were diagnosed with BXO, of whom 70 (42.8&#x0025;) were in the 51-60-year-old age group. They presented at the medical consultation at 3-9 months after onset of symptoms, where 124 (75.6&#x0025;) the patients were found to be with stage III of the disease. The most important comorbidities were found to be diabetes mellitus and obsesity, who were treated with potent steroids (betamethasone and clobetasol) with favorable results, with only nine (5.48&#x0025;) cases necessitating surgical treatment. In general, BXO is a rare, acquired, non-infectious and chronically inflammatory (autoimmune) skin disease that has an unknown etiology. Although the risk of developing this condition is particularly high in patients in the 40-60-year-old age group, it can occur at any age. In the present report, the majority of the patients presented after a long period of disease development, such that they were already in advanced stages of the condition with clinically subjective symptoms and severe sexual problems. This delay in diagnosis has several causes, including misdiagnosis, psychological issues, and sexual behavior. Diabetes mellitus and overweight/obesity tended to be important comorbidities of BXO since the majority of the patients were also affected by these conditions. These comorbidities can exert an important pathophysiological influence on BXO. The first-line treatment option for this condition is the local application of potent steroids, with favorable effects. Due to the risk of malignant transformation as a result of BXO, it is recommended that these patients should be followed up for a longer period.</p>
</abstract>
<kwd-group>
<kwd>balanitis xerotica obliterans</kwd>
<kwd>lichen sclerosus</kwd>
<kwd>diabetes</kwd>
<kwd>potent steroid</kwd>
<kwd>body mass index</kwd>
</kwd-group>
<funding-group>
<funding-statement><bold>Funding:</bold> No funding was received.</funding-statement>
</funding-group>
</article-meta>
</front>
<body>
<sec sec-type="intro">
<title>Introduction</title>
<p>Lichen sclerosus is a chronic disease of unknown etiology that can affect both sexes and commonly occur in the genital area. By contrast, balanitis xerotica obliterans (BXO) occurs only in the genital area of men and typically affects the foreskin, penile glans and/or the meatus (<xref rid="b1-ETM-23-5-11288" ref-type="bibr">1</xref>). In terms of etiology, it has been previously proposed that infections, especially sexually transmitted ones, trauma of the penis or chronic inflammatory conditions in the genital area can all cause or at least increase the risk of this condition (<xref rid="b2-ETM-23-5-11288" ref-type="bibr">2</xref>). However, accumulating evidence suggests that autoimmune mechanisms in association with other diseases, such as diabetes, genetic predispositions and/or inflammatory states of different causes, such as bacterial infections can all lead to the development of the disease (<xref rid="b3-ETM-23-5-11288 b4-ETM-23-5-11288 b5-ETM-23-5-11288" ref-type="bibr">3-5</xref>). As such, <italic>borrelia</italic> infection has been mentioned to be a possible etiological agent (<xref rid="b6-ETM-23-5-11288" ref-type="bibr">6</xref>). In addition, the lack of circumcision has been previously reported to be a risk factor for developing BXO. Although there is no race predilection, several studies have reported higher rates of this condition in African American and Hispanic populations due to lower rates of circumcision (<xref rid="b1-ETM-23-5-11288" ref-type="bibr">1</xref>,<xref rid="b7-ETM-23-5-11288" ref-type="bibr">7</xref>). The prevalence rate in England of lichen sclerosus is 0.1-0.3&#x0025;, whereas that of BXO in addition to the epidemiological data remains scarce (<xref rid="b8-ETM-23-5-11288" ref-type="bibr">8</xref>,<xref rid="b9-ETM-23-5-11288" ref-type="bibr">9</xref>). This is likely to be due to the initial presentation of the patients to physicians from a wide array of medical specialty backgrounds (<xref rid="b7-ETM-23-5-11288" ref-type="bibr">7</xref>,<xref rid="b8-ETM-23-5-11288" ref-type="bibr">8</xref>).</p>
<p>Clinically, this disease typically remains asymptomatic initially. Over time, physical examinations frequently reveal erythematous changes or white hypopigmented lesions on the glans penis or foreskin (<xref rid="b10-ETM-23-5-11288" ref-type="bibr">10</xref>). These erythematous changes can develop further into more defined lesions around the coronal sulcus and can progressively invade the urethral meatus and other anatomical regions (<xref rid="b10-ETM-23-5-11288" ref-type="bibr">10</xref>). The balanitis, as a form of generalized inflammation, can lead to phimosis, which can cause disruptions in micturition and disorders in sexual dynamics (<xref rid="b10-ETM-23-5-11288" ref-type="bibr">10</xref>). In advanced stages, erosions and ulcerations in the genital area can occur, which can be accompanied by local pruritus and/or pain, followed by local bacterial and/or fungal infections (<xref rid="b10-ETM-23-5-11288" ref-type="bibr">10</xref>,<xref rid="b11-ETM-23-5-11288" ref-type="bibr">11</xref>). The differential diagnosis includes neoplastic processes, autoimmune diseases, contact dermatitis, psoriasis, Zoon balanitis, leukoplakia, and fixed drug reaction (<xref rid="b10-ETM-23-5-11288" ref-type="bibr">10</xref>). Malignant transformation, especially to squamous cell carcinoma, occurs in 3-6&#x0025; of women and 2-8&#x0025; of men (<xref rid="b10-ETM-23-5-11288" ref-type="bibr">10</xref>,<xref rid="b12-ETM-23-5-11288" ref-type="bibr">12</xref>). For treatment, asymptomatic BXO does not require therapy (<xref rid="b12-ETM-23-5-11288" ref-type="bibr">12</xref>). For symptomatic lichen sclerosus, the main treatment method is the topical administration of potent steroids, including Betamethasone, Clobetasol, and Triamcinolone (<xref rid="b13-ETM-23-5-11288" ref-type="bibr">13</xref>). The surgical treatment option is circumcision, though this is only an option for severe phimosis reticent to local treatment (<xref rid="b13-ETM-23-5-11288" ref-type="bibr">13</xref>,<xref rid="b14-ETM-23-5-11288" ref-type="bibr">14</xref>).</p>
<p>The aim of the present observational, descriptive, retrospective study was to describe and analyze the clinical, epidemiological, and evolutionary characteristics of BXO in patients examined in daily practice. It is hoped that it reveals common characteristics of this condition that can deepen the understanding of this disease.</p>
</sec>
<sec sec-type="Materials|methods">
<title>Materials and methods</title>
<sec>
<title/>
<sec>
<title>Patients</title>
<p>An observational, descriptive, retrospective epidemiological clinical study was performed on data obtained from patients diagnosed with BXO between January 2006 and December 2020 from the casuistic of CMI DERMAMED (T&#x00E2;rgu Mure&#x0219;, Romania). Over this 15-year period, 164 patients were diagnosed with BXO in total. Written informed consent from the patients and ethics approval from CMI DERMAMED were obtained for the processing of personal patient data. Only one patient aged &#x003C;18 years was included in the present study. Informed consent signed by both parents was obtained for this patient. The average age was 47.52&#x00B1;10.00 years, ranging between 14 and 90 years. All patients were caucasian males and uncircumcised.</p>
</sec>
<sec>
<title>Diagnostic criteria</title>
<p>The diagnosis was established by dermatological clinical examination. The severity of this disease was defined by GLF, using the following criteria: i) Stage I, defined as clinical lesions without reported disturbances in sexual dynamics; ii) stage II, defined as clinical lesions with disorders in sexual dynamics; iii) stage III, defined as clinical lesions with sexual dynamic disorders and presence of phimosis, erosions and/or ulcerations. Patients were then assigned into clinical stages I, II,or III according to these criteria established. The exclusion criteria were: people without a diagnosis of BXO, and patients who have not signed the informed consent.</p>
</sec>
<sec>
<title>Study protocol</title>
<p>In the present study, GLF evaluated patients and collected data, including general data, disease onset, disease stage, sexual behavior, key personal history, present comorbidities, quality of life data, prescribed treatments, and disease progression. By contrast, other investigators, who were blinded to the clinical cases and treatment options, performed data analysis and the evaluation of the results. Due to data from the literature concerning a possible link between this disease and diabetes (<xref rid="b15-ETM-23-5-11288" ref-type="bibr">15</xref>), diabetes (blood glucose &#x003E;126 mg/dl) in patients previously known to be without diabetes were screened. All patients had their body mass index (BMI) calculated (normal, 18-24.9 kg/m<sup>2</sup>, overweight: 25-29.9 kg/m<sup>2</sup>, obese &#x003E;30 kg/m<sup>2</sup>) and were followed up for 2 years after the diagnosis of BXO by clinical examination and/or telephone interview. For collecting and analyzing the data, Excel program version 2016 (Microsoft Corporation) was used. The data are presented as case numbers, SD, and percentages.</p>
</sec>
</sec>
</sec>
<sec sec-type="Results">
<title>Results</title>
<sec>
<title/>
<sec>
<title>Demographic data</title>
<p>The cases were first categorized by age groups. In the 21-30 years age group, 10 (6.1&#x0025;) cases were found, whereas in the 31-40 years age group, 18 (10.9&#x0025;) cases were found. In the 41-50 years age group, 60 (36.6&#x0025;) cases were found. In the 51-60 years age group, there were 70 (42.8&#x0025;) cases, whilst 4 (2.4&#x0025;) cases were found in the 61-70 years age group. In total, one case (0.6&#x0025;) was seen in the &#x2264;20 years age group with one case (0.6&#x0025;) also observed in the &#x2265;70 years age group (<xref rid="tI-ETM-23-5-11288" ref-type="table">Table I</xref>).</p>
</sec>
<sec>
<title>Time between symptom onset and diagnosis</title>
<p>Regarding the time elapsed between the onset of first symptoms of the disease and clinical diagnosis, 3 (1.8&#x0025;) patients presented after 3 months, 15 (9.1&#x0025;) patients presented after 4 months, 44 (26.8&#x0025;) presented after 5 months, 51 (31.2&#x0025;) presented after 6 months, 33 (20.2&#x0025;) presented after 7 months, 13 (7.9&#x0025;) patients presented after 8 months and 5 (3&#x0025;) patients presented 9 months after the onset of symptoms of the disease (<xref rid="tII-ETM-23-5-11288" ref-type="table">Table II</xref>). The average time elapsed between the onset of the first symptoms of the disease and clinical diagnosis was 6.00&#x00B1;1.26 months.</p>
</sec>
<sec>
<title>Comorbidities</title>
<p>In terms of sexual behavior prior to the onset of the disease, 120 (73&#x0025;) of the patients reported undergoing extramarital and/or occasional sexual intercourse prior to BXO. Regarding comorbidities, it was found that 81 (49.3&#x0025;) of the studied patients were found with the comorbidity of diabetes mellitus and 91 (55.4&#x0025;) patients were either obese or overweight (<xref rid="tIII-ETM-23-5-11288" ref-type="table">Table III</xref>). Specifically, of the 81 (49.3&#x0025;) patients with diabetes, 70 (86,4&#x0025;) were found with confirmed type 2 diabetes and 11 (13.6&#x0025;) patients were found with type 1 diabetes (<xref rid="tIII-ETM-23-5-11288" ref-type="table">Table III</xref>). Based on anamnesis, only 70 patients were confirmed with diabetes at the moment of presentation (11 with type 1 diabetes; 59 with type 2 diabetes), whereas 11 were diagnosed with diabetes type 2 by screening (<xref rid="tIII-ETM-23-5-11288" ref-type="table">Table III</xref>). In terms of BMI, 91 patients (55.4&#x0025;) exhibited a higher BMI compared with normal. Amongst this group, 75 (82.4&#x0025;) patients were considered overweight with a mean BMI of 26.1&#x00B1;0.6, whereas 16 (17.6&#x0025;) patients were considered obese with a mean BMI of 31.20&#x00B1;0.42 (<xref rid="tIII-ETM-23-5-11288" ref-type="table">Table III</xref>).</p>
</sec>
<sec>
<title>Clinical data</title>
<p>When analyzing the severity of the disease, based on the criteria set in the present study, it was found that 124 (75.6&#x0025;) of the patients were at stage III of the disease, whereas 32 (19.5&#x0025;) were at stage II and only 8 (4.9&#x0025;) of the patients were at stage I. Dermatological lesions were found, in146 (89&#x0025;) cases located in the balano-foreskin area, in 12 (7.4&#x0025;) cases at the urinary meatus area, and in 6 (3.5&#x0025;) cases on the trunk of the penis (<xref rid="tIII-ETM-23-5-11288" ref-type="table">Table III</xref>). All patients were treated with potent local corticosteroids (mostly cream with betamethasone and clobetasol) with favorable outcome (lesion healing). During the follow-up period, 24 cases of relapse were reported, all of which were from patients with diabetes at stage III of disease, who belonged to the 41-50 (15 patients) and 51-60 years (9 patients) age group. Only 9 (5.48&#x0025;) of the cases required surgical treatment, namely circumcision. No cases of malignancy as a result of BXO were detected during the follow-up period.</p>
</sec>
</sec>
</sec>
<sec sec-type="Discussion">
<title>Discussion</title>
<p>BXO is an acquired, non-infectious chronic inflammatory skin disease with a controversial etiology (<xref rid="b2-ETM-23-5-11288" ref-type="bibr">2</xref>). It is such a rare disease that its true accurate incidence remains unknown. Boksh and Patwardhan (<xref rid="b8-ETM-23-5-11288" ref-type="bibr">8</xref>) have previously estimated the prevalence rate of lichen sclerosus to between 0.1 and 0.3&#x0025;. However, concerning the prevalence of BXO, epidemiological data remain scarce (<xref rid="b8-ETM-23-5-11288" ref-type="bibr">8</xref>). In terms of the age distribution of the disease, Kyriakis <italic>et al</italic> (<xref rid="b16-ETM-23-5-11288" ref-type="bibr">16</xref>) performed a clinical study on 51 cases of BXO, where among 20909 male patients, it was found that the majority of cases fell in the 51-60 years old age groups. This is consistent with the findings of the present study, where 70 (42.8&#x0025;) patients belonged to this age group and &#x003E;79&#x0025; of the cases are in the 40-60 years old age group. The reason could be that at that age, men are more prone to hormonal dysregulations, such that the risk of auto/immunological disorders is correspondingly increased (<xref rid="b17-ETM-23-5-11288" ref-type="bibr">17</xref>). In addition, the present study found that, the period of time between disease onset and when the patients present to medical consultation varied from 3 to 9 months with an average value of 6 months. Several explanations can be proposed for this delay in diagnosis. These patients are less likely to seek medical assistance because the early stages of the disease are almost entirely asymptomatic with only mild symptoms (such as itching) and no visible or painful lesions. They will typically only present to a medical consultation either if sexual intercourse is affected by the disease or after important local lesions have appeared, which are clearly visible and painful. These appear to correspond well with the results in the present study regarding the severity of this disease. The data showed that 124 (75.6&#x0025;) cases of the 164 in total seek medical consultation when they were already in a stage III of the disease. This stage was characterized by ulcerations and phimosis with visible and painful sclerotic plaques, which severely aggravated their sexual dynamic disorders. Another cause of this delayed diagnosis could be the absence of a precise diagnosis protocol for physicians, due to the lack of knowledge and early diagnostic indications of this disease. Nair (<xref rid="b16-ETM-23-5-11288" ref-type="bibr">16</xref>) previously stated that due to the asymptomatic nature of lichen sclerosus at the early stages of the disease and the lack of awareness by patients and doctors, the diagnosis is frequently delayed. Furthermore, a cause may also be the initial presentation of the patients to physicians from a wide array of specialty backgrounds, since BXO lies on the borderline of different medical disciplines (<xref rid="b18-ETM-23-5-11288" ref-type="bibr">18</xref>). BXO can also cause psychological problems, including embarrassment, shame and emotional stress, which will prevent patients from seeking medical assistance. Virgili <italic>et al</italic> (<xref rid="b19-ETM-23-5-11288" ref-type="bibr">19</xref>) previously performed a multicenter Italian study on 729 cases of lichens sclerosus, which observed a mean diagnostic delay of 3.5 years for men in the case of BXO. This previous study continued to state that because BXO is commonly located on the genitals, patients tend to feel more ashamed to visit a medical office (<xref rid="b19-ETM-23-5-11288" ref-type="bibr">19</xref>). Another cause of this delay is the anamnesis data on sexual behavior, namely extramarital sexual intercourse, prior to the onset of BXO, which was present in 120 (73&#x0025;) of all patients included in the present study. The majority of patients considered that the cause of this disease was the acquisition of infection due to the extramarital sexual act. Relevant reasons for these could be that men tend to have sexual intercourse without protection, with different individuals, increasing the risk of possible bacterial and viral infections, such as Epstein-Barr or Human Papilloma Virus, which can also serve an etiological role in the manifestation of BXO (<xref rid="b20-ETM-23-5-11288" ref-type="bibr">20</xref>). Since other relevant studies corresponding to these findings are not openly available for comparison, further clear and pertinent data are required (<xref rid="b20-ETM-23-5-11288" ref-type="bibr">20</xref>,<xref rid="b21-ETM-23-5-11288" ref-type="bibr">21</xref>).</p>
<p>The most frequent comorbidities in the studied group in the present study were diabetes and obesity. It was found that 81 (49.3&#x0025;) of the studied patients presented with diabetes mellitus, where 91 (55.4&#x0025;) of the patients were either obese or overweight. The presence of these comorbidities would suggest a sedentary lifestyle, which is causing overweight/obesity, in turn promoting general metabolic diseases, such as diabetes mellitus or hypertension. These may serve to be important etio-pathological factors in the development of BXO, in addition to the genetic or autoimmune disposition. Hofer <italic>et al</italic> (<xref rid="b15-ETM-23-5-11288" ref-type="bibr">15</xref>) previously found a significant association between the BMI and lichen sclerosus, in addition to between diabetes mellitus and penile lichen sclerosus. In addition, the majority of the patients are presenting whilst they were already at advanced stages of lichen sclerosus. Following analysis of the data regarding the age of the patients and the stage of the disease, all the patients at stage III of the disease belonged to the age groups of 41-50 and 51-60 years. Correspondingly, all patients with diabetes and higher BMI were at stage III of the disease. All patients were treated with potent local corticosteroids (mainly cream with betamethasone and clobetasol), the first-line treatment option for this disease (<xref rid="b22-ETM-23-5-11288" ref-type="bibr">22</xref>). The majority of patients exhibited favorable outcomes. Furthermore, potent steroid treatment has yielded favorable results in cases of multiple relapse following other types of treatment. Only 9 (5.48&#x0025;) of the cases required surgical treatment, namely circumcision. Kirtschig <italic>et al</italic> (<xref rid="b22-ETM-23-5-11288" ref-type="bibr">22</xref>) previously revealed that clobetasol propionate and pimecrolimus are both effective treatment strategies for the case of BXO, but clobetasol propionate should be used as the first-line treatment. Other treatment options can also be used, specifically testosterone ointment, ciclosporin, retinoids, UVA light, laser, stanazolol, which reported different outcomes (<xref rid="b23-ETM-23-5-11288 b24-ETM-23-5-11288 b25-ETM-23-5-11288 b26-ETM-23-5-11288 b27-ETM-23-5-11288 b28-ETM-23-5-11288 b29-ETM-23-5-11288" ref-type="bibr">23-29</xref>). Malignant transformation, especially to squamous cell carcinoma, can occur in 3-6&#x0025; of females and 2-8&#x0025; of males after 5 years (<xref rid="b30-ETM-23-5-11288 b31-ETM-23-5-11288 b32-ETM-23-5-11288" ref-type="bibr">30-32</xref>) No cases of malignancy following BXO were detected during the follow-up period in the present study. The majority of the patients are presenting already at advanced stages, exhibiting clinical symptoms and severe sexual dynamic problems. This delay in diagnosis can have a number of causes, such as the lack of diagnosis, psychological issues, and sexual behavior. Diabetes mellitus and overweight/obesity were found to be important comorbidities for BXO, since a substantial proportion of the patients were affected. These comorbidities may have important etiological implications. The first-line treatment option is local potent steroids, which conferred beneficial effects. Due to the risk of malignant transformation as a result of BXO, these patients should be followed up for a longer period of time.</p>
</sec>
</body>
<back>
<ack>
<title>Acknowledgements</title>
<p>Not applicable.</p>
</ack>
<sec sec-type="data-availability">
<title>Availability of data and materials</title>
<p>All data generated or analyzed during this study are included in this published article.</p>
</sec>
<sec>
<title>Authors&#x0027; contributions</title>
<p>GLF was responsible for the clinical management of the cases, the design of the study, the evaluation, and the analysis of data. LF and DB made substantial contributions to the conception and design of the study and the preparation of the manuscript. DSK, IB and LF were responsible for the analysis and interpretation of data and revision of the manuscript. GLF and FL are responsible for confirming the authenticity of all the raw data. All authors have read and approved the final manuscript.</p>
</sec>
<sec>
<title>Ethics approval and consent to participate</title>
<p>Ethics approval was obtained from the Ethics Committee for Research of the CMI DERMAMED private medical office (approval no. 27/2021). Written informed consent from the patients was obtained. One patient aged &#x003C;18 years was included in the present study. Informed consent signed by both parents was obtained for this patient.</p>
</sec>
<sec>
<title>Patient consent for publication</title>
<p>Not applicable.</p>
</sec>
<sec sec-type="COI-statement">
<title>Competing interests</title>
<p>The authors declare that they have no competing interests.</p>
</sec>
<ref-list>
<title>References</title>
<ref id="b1-ETM-23-5-11288"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nguyen</surname><given-names>ATM</given-names></name><name><surname>Holland</surname><given-names>AJA</given-names></name></person-group><article-title>Balanitis xerotica obliterans: An update for clinicians</article-title><source>Eur J Pediatr</source><volume>179</volume><fpage>9</fpage><lpage>16</lpage><year>2020</year><pub-id pub-id-type="pmid">31760506</pub-id><pub-id pub-id-type="doi">10.1007/s00431-019-03516-3</pub-id></element-citation></ref>
<ref id="b2-ETM-23-5-11288"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Das</surname><given-names>S</given-names></name><name><surname>Tunuguntla</surname><given-names>HS</given-names></name></person-group><article-title>Balanitis xerotica obliterans-a review</article-title><source>World J Urol</source><volume>18</volume><fpage>382</fpage><lpage>387</lpage><year>2000</year><pub-id pub-id-type="pmid">11204255</pub-id><pub-id pub-id-type="doi">10.1007/PL00007083</pub-id></element-citation></ref>
<ref id="b3-ETM-23-5-11288"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Celis</surname><given-names>S</given-names></name><name><surname>Reed</surname><given-names>F</given-names></name><name><surname>Murphy</surname><given-names>F</given-names></name><name><surname>Adams</surname><given-names>S</given-names></name><name><surname>Gillick</surname><given-names>J</given-names></name><name><surname>Abdelhafeez</surname><given-names>AH</given-names></name><name><surname>Lopez</surname><given-names>PJ</given-names></name></person-group><article-title>Balanitis xerotica obliterans in children and adolescents: A literature review and clinical series</article-title><source>J Pediatr Urol</source><volume>10</volume><fpage>34</fpage><lpage>39</lpage><year>2014</year><pub-id pub-id-type="pmid">24295833</pub-id><pub-id pub-id-type="doi">10.1016/j.jpurol.2013.09.027</pub-id></element-citation></ref>
<ref id="b4-ETM-23-5-11288"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dickie</surname><given-names>RJ</given-names></name><name><surname>Horne</surname><given-names>CH</given-names></name><name><surname>Sutherland</surname><given-names>HW</given-names></name><name><surname>Bewsher</surname><given-names>PD</given-names></name><name><surname>Stankler</surname><given-names>L</given-names></name></person-group><article-title>Direct evidence of localized immunologic damage in lichen sclerosus et atrophicus</article-title><source>J Clin Pathol</source><volume>35</volume><fpage>1395</fpage><lpage>1399</lpage><year>1982</year><pub-id pub-id-type="pmid">7174851</pub-id><pub-id pub-id-type="doi">10.1136/jcp.35.12.1395-c</pub-id></element-citation></ref>
<ref id="b5-ETM-23-5-11288"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meyrick Thomas</surname><given-names>RH</given-names></name><name><surname>Ridley</surname><given-names>CM</given-names></name><name><surname>Black</surname><given-names>MM</given-names></name></person-group><article-title>The association of lichen sclerosus atrophicus and autoimmune-related disease in males</article-title><source>Br J Dermatol</source><volume>109</volume><fpage>661</fpage><lpage>664</lpage><year>1983</year><pub-id pub-id-type="pmid">6652042</pub-id><pub-id pub-id-type="doi">10.1111/j.1365-2133.1983.tb00546.x</pub-id></element-citation></ref>
<ref id="b6-ETM-23-5-11288"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fujiwara</surname><given-names>H</given-names></name><name><surname>Fujiwara</surname><given-names>K</given-names></name><name><surname>Hashimoto</surname><given-names>K</given-names></name><name><surname>Mehregan</surname><given-names>AH</given-names></name><name><surname>Schaumburg-Lever</surname><given-names>G</given-names></name><name><surname>Lange</surname><given-names>R</given-names></name><name><surname>Schempp</surname><given-names>C</given-names></name><name><surname>Gollnick</surname><given-names>H</given-names></name></person-group><article-title>Detection of Borrelia burgdorferi DNA (B. garinii or B. afzelii) in morphoea and lichen sclerosus et atrophicus tissue of German and Japanese but not of US patients</article-title><source>Arch Dermatol</source><volume>133</volume><fpage>41</fpage><lpage>44</lpage><year>1997</year><pub-id pub-id-type="pmid">9006371</pub-id></element-citation></ref>
<ref id="b7-ETM-23-5-11288"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mazzoni</surname><given-names>D</given-names></name><name><surname>Pool</surname><given-names>L</given-names></name><name><surname>Muir</surname><given-names>J</given-names></name></person-group><article-title>Pathologically oriented descriptive study of male genital circumcisions across medical and surgical specialties</article-title><source>Int J Dermatol</source><volume>60</volume><fpage>559</fpage><lpage>563</lpage><year>2021</year><pub-id pub-id-type="pmid">33319352</pub-id><pub-id pub-id-type="doi">10.1111/ijd.15359</pub-id></element-citation></ref>
<ref id="b8-ETM-23-5-11288"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boksh</surname><given-names>K</given-names></name><name><surname>Patwardhan</surname><given-names>N</given-names></name></person-group><article-title>Balanitis xerotica obliterans: Has its diagnostic accuracy improved with time?</article-title><source>JRSM Open</source><volume>8</volume><issue>2054270417692731</issue><year>2017</year><pub-id pub-id-type="pmid">28620502</pub-id><pub-id pub-id-type="doi">10.1177/2054270417692731</pub-id></element-citation></ref>
<ref id="b9-ETM-23-5-11288"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pradhan</surname><given-names>A</given-names></name><name><surname>Patel</surname><given-names>R</given-names></name><name><surname>Said</surname><given-names>AJ</given-names></name><name><surname>Upadhyaya</surname><given-names>M</given-names></name></person-group><article-title>10 years&#x0027; experience in balanitis xerotica obliterans: A single-institution study</article-title><source>Eur J Pediatr Surg</source><volume>29</volume><fpage>302</fpage><lpage>306</lpage><year>2019</year><pub-id pub-id-type="pmid">30130825</pub-id><pub-id pub-id-type="doi">10.1055/s-0038-1668562</pub-id></element-citation></ref>
<ref id="b10-ETM-23-5-11288"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fergus</surname><given-names>KB</given-names></name><name><surname>Lee</surname><given-names>AW</given-names></name><name><surname>Baradaran</surname><given-names>N</given-names></name><name><surname>Cohen</surname><given-names>AJ</given-names></name><name><surname>Stohr</surname><given-names>BA</given-names></name><name><surname>Erickson</surname><given-names>BA</given-names></name><name><surname>Mmonu</surname><given-names>NA</given-names></name><name><surname>Breyer</surname><given-names>BN</given-names></name></person-group><article-title>Pathophysiology, clinical manifestations, and treatment of lichen sclerosus: A systematic review</article-title><source>Urology</source><volume>135</volume><fpage>11</fpage><lpage>19</lpage><year>2020</year><pub-id pub-id-type="pmid">31605681</pub-id><pub-id pub-id-type="doi">10.1016/j.urology.2019.09.034</pub-id></element-citation></ref>
<ref id="b11-ETM-23-5-11288"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Clouston</surname><given-names>D</given-names></name><name><surname>Hall</surname><given-names>A</given-names></name><name><surname>Lawrentschuk</surname><given-names>N</given-names></name></person-group><article-title>Penile lichen sclerosus (balanitis xerotica obliterans)</article-title><source>BJU Int</source><volume>108 (Suppl 2)</volume><fpage>S14</fpage><lpage>S19</lpage><year>2011</year><pub-id pub-id-type="pmid">22085120</pub-id><pub-id pub-id-type="doi">10.1111/j.1464-410X.2011.10699.x</pub-id></element-citation></ref>
<ref id="b12-ETM-23-5-11288"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Philippou</surname><given-names>P</given-names></name><name><surname>Shabbir</surname><given-names>M</given-names></name><name><surname>Ralph</surname><given-names>DJ</given-names></name><name><surname>Malone</surname><given-names>P</given-names></name><name><surname>Nigam</surname><given-names>R</given-names></name><name><surname>Freeman</surname><given-names>A</given-names></name><name><surname>Muneer</surname><given-names>A</given-names></name><name><surname>Minhas</surname><given-names>S</given-names></name></person-group><article-title>Genital lichen sclerosus/balanitis xerotica obliterans in men with penile carcinoma: A critical analysis</article-title><source>BJU Int</source><volume>111</volume><fpage>970</fpage><lpage>976</lpage><year>2013</year><pub-id pub-id-type="pmid">23356463</pub-id><pub-id pub-id-type="doi">10.1111/j.1464-410X.2012.11773.x</pub-id></element-citation></ref>
<ref id="b13-ETM-23-5-11288"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Buechner</surname><given-names>SA</given-names></name></person-group><article-title>Common skin disorders of the penis</article-title><source>BJU Int</source><volume>90</volume><fpage>498</fpage><lpage>506</lpage><year>2002</year><pub-id pub-id-type="pmid">12175386</pub-id><pub-id pub-id-type="doi">10.1046/j.1464-410x.2002.02962.x</pub-id></element-citation></ref>
<ref id="b14-ETM-23-5-11288"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Folaranmi</surname><given-names>SE</given-names></name><name><surname>Corbett</surname><given-names>HJ</given-names></name><name><surname>Losty</surname><given-names>PD</given-names></name></person-group><article-title>Does application, of topical steroids for lichen sclerosus (balanitis xerotica obliterans) affect the rate of circumcision? A systematic review</article-title><source>J Pediatr Surg</source><volume>53</volume><fpage>2225</fpage><lpage>2227</lpage><year>2018</year><pub-id pub-id-type="pmid">29395150</pub-id><pub-id pub-id-type="doi">10.1016/j.jpedsurg.2017.12.021</pub-id></element-citation></ref>
<ref id="b15-ETM-23-5-11288"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hofer</surname><given-names>MD</given-names></name><name><surname>Meeks</surname><given-names>JJ</given-names></name><name><surname>Mehdiratta</surname><given-names>N</given-names></name><name><surname>Granieri</surname><given-names>MA</given-names></name><name><surname>Cashy</surname><given-names>J</given-names></name><name><surname>Gonzalez</surname><given-names>CM</given-names></name></person-group><article-title>Lichen sclerosus in men is associated with elevated body mass index, diabetes mellitus, coronary artery disease, and smoking</article-title><source>World J Urol</source><volume>32</volume><fpage>105</fpage><lpage>108</lpage><year>2014</year><pub-id pub-id-type="pmid">23633127</pub-id><pub-id pub-id-type="doi">10.1007/s00345-013-1090-7</pub-id></element-citation></ref>
<ref id="b16-ETM-23-5-11288"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kyriakis</surname><given-names>KP</given-names></name><name><surname>Emmanuelides</surname><given-names>S</given-names></name><name><surname>Terzoudi</surname><given-names>S</given-names></name><name><surname>Palamaras</surname><given-names>I</given-names></name><name><surname>Damoulaki</surname><given-names>E</given-names></name><name><surname>Evangelou</surname><given-names>G</given-names></name></person-group><article-title>Gender and age prevalence distributions of morphea en plaque and anogenital lichen sclerosus</article-title><source>J Eur Acad Dermatol Venereol</source><volume>21</volume><fpage>825</fpage><lpage>826</lpage><year>2007</year><pub-id pub-id-type="pmid">17567317</pub-id><pub-id pub-id-type="doi">10.1111/j.1468-3083.2006.01954.x</pub-id></element-citation></ref>
<ref id="b17-ETM-23-5-11288"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kreuter</surname><given-names>A</given-names></name><name><surname>Kryvosheyeva</surname><given-names>Y</given-names></name><name><surname>Terras</surname><given-names>S</given-names></name><name><surname>Moritz</surname><given-names>R</given-names></name><name><surname>M&#x00F6;llenhoff</surname><given-names>K</given-names></name><name><surname>Altmeyer</surname><given-names>P</given-names></name><name><surname>Scola</surname><given-names>N</given-names></name><name><surname>Gambichler</surname><given-names>T</given-names></name></person-group><article-title>Association of autoimmune diseases with lichen sclerosus in 532 male and female patients</article-title><source>Acta Derm Venereol</source><volume>93</volume><fpage>238</fpage><lpage>241</lpage><year>2013</year><pub-id pub-id-type="pmid">23224274</pub-id><pub-id pub-id-type="doi">10.2340/00015555-1512</pub-id></element-citation></ref>
<ref id="b18-ETM-23-5-11288"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nair</surname><given-names>PA</given-names></name></person-group><article-title>Vulvar lichen sclerosus et atrophicus</article-title><source>J Midlife Health</source><volume>8</volume><fpage>55</fpage><lpage>62</lpage><year>2017</year><pub-id pub-id-type="pmid">28706405</pub-id><pub-id pub-id-type="doi">10.4103/jmh.JMH_13_17</pub-id></element-citation></ref>
<ref id="b19-ETM-23-5-11288"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Virgili</surname><given-names>A</given-names></name><name><surname>Borghi</surname><given-names>A</given-names></name><name><surname>Cazzaniga</surname><given-names>S</given-names></name><name><surname>Di Landro</surname><given-names>A</given-names></name><name><surname>Naldi</surname><given-names>L</given-names></name><name><surname>Minghetti</surname><given-names>S</given-names></name><name><surname>Verrone</surname><given-names>A</given-names></name><name><surname>Stroppiana</surname><given-names>E</given-names></name><name><surname>Caproni</surname><given-names>M</given-names></name><name><surname>Nasca</surname><given-names>MR</given-names></name><etal/></person-group><article-title>New insights into potential risk factors and associations in genital lichen sclerosus: Data from a multicentre Italian study on 729 consecutive cases</article-title><source>J Eur Acad Dermatol Venereol</source><volume>31</volume><fpage>699</fpage><lpage>704</lpage><year>2017</year><pub-id pub-id-type="pmid">27515901</pub-id><pub-id pub-id-type="doi">10.1111/jdv.13867</pub-id></element-citation></ref>
<ref id="b20-ETM-23-5-11288"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>A</given-names></name><name><surname>Fischer</surname><given-names>G</given-names></name></person-group><article-title>Diagnosis and treatment of vulvar lichen sclerosus: An update for dermatologists</article-title><source>Am J Clin Dermatol</source><volume>19</volume><fpage>695</fpage><lpage>706</lpage><year>2018</year><pub-id pub-id-type="pmid">29987650</pub-id><pub-id pub-id-type="doi">10.1007/s40257-018-0364-7</pub-id></element-citation></ref>
<ref id="b21-ETM-23-5-11288"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kirtschig</surname><given-names>G</given-names></name></person-group><article-title>Lichen sclerosus: Symptoms, diagnosis, therapeutic procedures</article-title><source>Hautarzt</source><volume>69</volume><fpage>127</fpage><lpage>133</lpage><year>2018</year><pub-id pub-id-type="pmid">29340709</pub-id><pub-id pub-id-type="doi">10.1007/s00105-017-4121-2</pub-id><comment>(In German)</comment></element-citation></ref>
<ref id="b22-ETM-23-5-11288"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kirtschig</surname><given-names>G</given-names></name><name><surname>Becker</surname><given-names>K</given-names></name><name><surname>G&#x00FC;nthert</surname><given-names>A</given-names></name><name><surname>Jasaitiene</surname><given-names>D</given-names></name><name><surname>Cooper</surname><given-names>S</given-names></name><name><surname>Chi</surname><given-names>CC</given-names></name><name><surname>Kreuter</surname><given-names>A</given-names></name><name><surname>Rall</surname><given-names>KK</given-names></name><name><surname>Aberer</surname><given-names>W</given-names></name><name><surname>Riechardt</surname><given-names>S</given-names></name><etal/></person-group><article-title>Evidence-based (S3) Guideline on (anogenital) Lichen sclerosus</article-title><source>J Eur Acad Dermatol Venereol</source><volume>29</volume><fpage>e1</fpage><lpage>e43</lpage><year>2015</year><pub-id pub-id-type="pmid">26202852</pub-id><pub-id pub-id-type="doi">10.1111/jdv.13136</pub-id></element-citation></ref>
<ref id="b23-ETM-23-5-11288"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chung</surname><given-names>ASJ</given-names></name><name><surname>Suarez</surname><given-names>OA</given-names></name></person-group><article-title>Current treatment of lichen sclerosus and stricture</article-title><source>World J Urol</source><volume>38</volume><fpage>3061</fpage><lpage>3067</lpage><year>2020</year><pub-id pub-id-type="pmid">31807846</pub-id><pub-id pub-id-type="doi">10.1007/s00345-019-03030-z</pub-id></element-citation></ref>
<ref id="b24-ETM-23-5-11288"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tran</surname><given-names>DA</given-names></name><name><surname>Tan</surname><given-names>X</given-names></name><name><surname>Macri</surname><given-names>CJ</given-names></name><name><surname>Goldstein</surname><given-names>AT</given-names></name><name><surname>Fu</surname><given-names>SW</given-names></name></person-group><article-title>Lichen sclerosus: An autoimmunopathogenic and genomic enigma with emerging genetic and immune targets</article-title><source>Int J Biol Sci</source><volume>15</volume><fpage>1429</fpage><lpage>1439</lpage><year>2019</year><pub-id pub-id-type="pmid">31337973</pub-id><pub-id pub-id-type="doi">10.7150/ijbs.34613</pub-id></element-citation></ref>
<ref id="b25-ETM-23-5-11288"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tatu</surname><given-names>AL</given-names></name><name><surname>Nwabudike</surname><given-names>LC</given-names></name></person-group><comment>The treatment options of male genital Lichen sclerosus et atrophicus: Treatments of genital Lichen sclerosus. In: Proceedings of the 14th National Congress of Urogynecology and the National Conference of the Romanian Association for the Study of Pain, Eforie, pp262-264, 2017.</comment></element-citation></ref>
<ref id="b26-ETM-23-5-11288"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mautz</surname><given-names>TT</given-names></name><name><surname>Krapf</surname><given-names>JM</given-names></name><name><surname>Goldstein</surname><given-names>AT</given-names></name></person-group><article-title>Topical corticosteroids in the treatment of vulvar lichen sclerosus: A review of pharmacokinetics and recommended dosing frequencies</article-title><source>Sex Med Rev</source><volume>10</volume><fpage>42</fpage><lpage>52</lpage><year>2022</year><pub-id pub-id-type="pmid">34226161</pub-id><pub-id pub-id-type="doi">10.1016/j.sxmr.2021.03.006</pub-id></element-citation></ref>
<ref id="b27-ETM-23-5-11288"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bizjak Ogrinc</surname><given-names>U</given-names></name><name><surname>Sen&#x010D;ar</surname><given-names>S</given-names></name><name><surname>Luzar</surname><given-names>B</given-names></name><name><surname>Lukanovi&#x0107;</surname><given-names>A</given-names></name></person-group><article-title>Efficacy of non-ablative laser therapy for lichen sclerosus: A randomized controlled trial</article-title><source>J Obstet Gynaecol Can</source><volume>41</volume><fpage>1717</fpage><lpage>1725</lpage><year>2019</year><pub-id pub-id-type="pmid">30981618</pub-id><pub-id pub-id-type="doi">10.1016/j.jogc.2019.01.023</pub-id></element-citation></ref>
<ref id="b28-ETM-23-5-11288"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tatu</surname><given-names>AL</given-names></name><name><surname>Nwabudike</surname><given-names>LC</given-names></name></person-group><article-title>Male genital lichen sclerosus-a permanent therapeutic challenge</article-title><source>J Am Acad Dermatol</source><volume>79 (Suppl 1)</volume><issue>AB185</issue><year>2018</year></element-citation></ref>
<ref id="b29-ETM-23-5-11288"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fekete</surname><given-names>GL</given-names></name><name><surname>Cotoi</surname><given-names>OS</given-names></name><name><surname>Fekete</surname><given-names>JE</given-names></name></person-group><article-title>Multiple nodular cutaneous metastasis as first clinical sign of signet ring cell gastric carcinoma: Case report</article-title><source>Acta Dermatovenerol Croat</source><volume>20</volume><fpage>34</fpage><lpage>37</lpage><year>2012</year><pub-id pub-id-type="pmid">22507473</pub-id></element-citation></ref>
<ref id="b30-ETM-23-5-11288"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Neill</surname><given-names>SM</given-names></name><name><surname>Tatnall</surname><given-names>FM</given-names></name><name><surname>Cox</surname><given-names>NH</given-names></name></person-group><comment>British Association of Dermatologists</comment><article-title>Guidelines for the management of lichen sclerosus</article-title><source>Br J Dermatol</source><volume>147</volume><fpage>640</fpage><lpage>649</lpage><year>2002</year><pub-id pub-id-type="pmid">12366407</pub-id><pub-id pub-id-type="doi">10.1046/j.1365-2133.2002.05012.x</pub-id></element-citation></ref>
<ref id="b31-ETM-23-5-11288"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bleeker</surname><given-names>MC</given-names></name><name><surname>Visser</surname><given-names>PJ</given-names></name><name><surname>Overbeek</surname><given-names>LI</given-names></name><name><surname>Van Beurden</surname><given-names>M</given-names></name><name><surname>Berkhof</surname><given-names>J</given-names></name></person-group><article-title>Lichen sclerosus: Incidence and risk of vulvar squamous cell carcinoma</article-title><source>Cancer Epidemiol Biomarkers Prev</source><volume>25</volume><fpage>1224</fpage><lpage>1230</lpage><year>2016</year><pub-id pub-id-type="pmid">27257093</pub-id><pub-id pub-id-type="doi">10.1158/1055-9965.EPI-16-0019</pub-id></element-citation></ref>
<ref id="b32-ETM-23-5-11288"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Powell</surname><given-names>J</given-names></name><name><surname>Robson</surname><given-names>A</given-names></name><name><surname>Cranston</surname><given-names>D</given-names></name><name><surname>Wojnarowska</surname><given-names>F</given-names></name><name><surname>Turner</surname><given-names>R</given-names></name></person-group><article-title>High incidence of lichen sclerosus in patients with squamous cell carcinoma of the penis</article-title><source>Br J Dermatol</source><volume>145</volume><fpage>85</fpage><lpage>89</lpage><year>2001</year><pub-id pub-id-type="pmid">11453912</pub-id><pub-id pub-id-type="doi">10.1046/j.1365-2133.2001.04287.x</pub-id></element-citation></ref>
</ref-list>
</back>
<floats-group>
<table-wrap id="tI-ETM-23-5-11288" position="float">
<label>Table I</label>
<caption><p>Clinical results and comorbidities sorted by age group.</p></caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="left" valign="middle">Age group</th>
<th align="center" valign="middle">&#x2264;20 years (&#x0025;)</th>
<th align="center" valign="middle">21-30 years (&#x0025;)</th>
<th align="center" valign="middle">31-40 years (&#x0025;)</th>
<th align="center" valign="middle">41-50 years (&#x0025;)</th>
<th align="center" valign="middle">51-60 years (&#x0025;)</th>
<th align="center" valign="middle">61-70 years (&#x0025;)</th>
<th align="center" valign="middle">&#x2265;70 years (&#x0025;)</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" valign="middle">Total number of cases, N/&#x0025;</td>
<td align="center" valign="middle">1 (0.6)</td>
<td align="center" valign="middle">10 (6.1)</td>
<td align="center" valign="middle">18 (10.9)</td>
<td align="center" valign="middle">60 (36.6)</td>
<td align="center" valign="middle">70 (42.8)</td>
<td align="center" valign="middle">4 (2.4)</td>
<td align="center" valign="middle">1 (0.6)</td>
</tr>
<tr>
<td align="left" valign="middle">&#x00A0;&#x00A0;&#x00A0;&#x00A0;&#x00A0;Stage I, N</td>
<td align="center" valign="middle">1 (0.6)</td>
<td align="center" valign="middle">3 (1.8)</td>
<td align="center" valign="middle">4 (2.4)</td>
<td align="center" valign="middle">-</td>
<td align="center" valign="middle">-</td>
<td align="center" valign="middle">-</td>
<td align="center" valign="middle">-</td>
</tr>
<tr>
<td align="left" valign="middle">&#x00A0;&#x00A0;&#x00A0;&#x00A0;&#x00A0;Stage II, N</td>
<td align="center" valign="middle">-</td>
<td align="center" valign="middle">7 (4.3)</td>
<td align="center" valign="middle">14 (8.5)</td>
<td align="center" valign="middle">4 (2.4)</td>
<td align="center" valign="middle">2 (1.3)</td>
<td align="center" valign="middle">4 (2.4)</td>
<td align="center" valign="middle">1 (0.6)</td>
</tr>
<tr>
<td align="left" valign="middle">&#x00A0;&#x00A0;&#x00A0;&#x00A0;&#x00A0;Stage III, N</td>
<td align="center" valign="middle">-</td>
<td align="center" valign="middle">-</td>
<td align="center" valign="middle">-</td>
<td align="center" valign="middle">56 (34.2)</td>
<td align="center" valign="middle">68 (41.5)</td>
<td align="center" valign="middle">-</td>
<td align="center" valign="middle">-</td>
</tr>
<tr>
<td align="left" valign="middle">Diabetes, N</td>
<td align="center" valign="middle">-</td>
<td align="center" valign="middle">-</td>
<td align="center" valign="middle">-</td>
<td align="center" valign="middle">40 (49.3)</td>
<td align="center" valign="middle">41 (50.7)</td>
<td align="center" valign="middle">-</td>
<td align="center" valign="middle">-</td>
</tr>
<tr>
<td align="left" valign="middle">High BMI (&#x003E;25 kg/m<sup>2</sup>), N (/&#x0025;)</td>
<td align="center" valign="middle">-</td>
<td align="center" valign="middle">2 (2.2)</td>
<td align="center" valign="middle">4 (4.4)</td>
<td align="center" valign="middle">40(44)</td>
<td align="center" valign="middle">41(45)</td>
<td align="center" valign="middle">4 (4.4)</td>
<td align="center" valign="middle">-</td>
</tr>
</tbody>
</table>
</table-wrap>
<table-wrap id="tII-ETM-23-5-11288" position="float">
<label>Table II</label>
<caption><p>Delay of diagnosis.</p></caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="left" valign="middle">Delay of diagnosis</th>
<th align="center" valign="middle">3 months (&#x0025;)</th>
<th align="center" valign="middle">4 months (&#x0025;)</th>
<th align="center" valign="middle">5 months (&#x0025;)</th>
<th align="center" valign="middle">6 months (&#x0025;)</th>
<th align="center" valign="middle">7 months (&#x0025;)</th>
<th align="center" valign="middle">8 months (&#x0025;)</th>
<th align="center" valign="middle">9 months (&#x0025;)</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" valign="middle">Number of cases</td>
<td align="center" valign="middle">3 (1.8)</td>
<td align="center" valign="middle">15 (9.1)</td>
<td align="center" valign="middle">44 (26.8)</td>
<td align="center" valign="middle">51 (31.2)</td>
<td align="center" valign="middle">33 (20.2)</td>
<td align="center" valign="middle">13 (7.9)</td>
<td align="center" valign="middle">5(3)</td>
</tr>
</tbody>
</table>
</table-wrap>
<table-wrap id="tIII-ETM-23-5-11288" position="float">
<label>Table III</label>
<caption><p>Clinical results and comorbidities.</p></caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="left" valign="middle">Parameter</th>
<th align="center" valign="middle">N (&#x0025;)</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" valign="middle">Area of penis</td>
<td align="center" valign="middle">&#x00A0;</td>
</tr>
<tr>
<td align="left" valign="middle">&#x00A0;&#x00A0;&#x00A0;&#x00A0;&#x00A0;Balano-foreskin area</td>
<td align="center" valign="middle">146(89)</td>
</tr>
<tr>
<td align="left" valign="middle">&#x00A0;&#x00A0;&#x00A0;&#x00A0;&#x00A0;Meatus area</td>
<td align="center" valign="middle">12.0 (7.4)</td>
</tr>
<tr>
<td align="left" valign="middle">&#x00A0;&#x00A0;&#x00A0;&#x00A0;&#x00A0;Trunk of the penis</td>
<td align="center" valign="middle">6 (3.5)</td>
</tr>
<tr>
<td align="left" valign="middle">Severity of balanitis xerotica obliterans</td>
<td align="center" valign="middle">&#x00A0;</td>
</tr>
<tr>
<td align="left" valign="middle">&#x00A0;&#x00A0;&#x00A0;&#x00A0;&#x00A0;Stage I</td>
<td align="center" valign="middle">8 (4.9)</td>
</tr>
<tr>
<td align="left" valign="middle">&#x00A0;&#x00A0;&#x00A0;&#x00A0;&#x00A0;Stage II</td>
<td align="center" valign="middle">32 (19.5)</td>
</tr>
<tr>
<td align="left" valign="middle">&#x00A0;&#x00A0;&#x00A0;&#x00A0;&#x00A0;Stage III</td>
<td align="center" valign="middle">124 (75.6)</td>
</tr>
<tr>
<td align="left" valign="middle">Diabetes (n=81)</td>
<td align="center" valign="middle">&#x00A0;</td>
</tr>
<tr>
<td align="left" valign="middle">&#x00A0;&#x00A0;&#x00A0;&#x00A0;&#x00A0;Confirmed</td>
<td align="center" valign="middle">70 (86.4)</td>
</tr>
<tr>
<td align="left" valign="middle">&#x00A0;&#x00A0;&#x00A0;&#x00A0;&#x00A0;New detected</td>
<td align="center" valign="middle">11 (13.6)</td>
</tr>
<tr>
<td align="left" valign="middle">BMI</td>
<td align="center" valign="middle">&#x00A0;</td>
</tr>
<tr>
<td align="left" valign="middle">&#x00A0;&#x00A0;&#x00A0;&#x00A0;&#x00A0;High &#x003E;25.0</td>
<td align="center" valign="middle">91 (55.4)</td>
</tr>
<tr>
<td align="left" valign="middle">&#x00A0;&#x00A0;&#x00A0;&#x00A0;&#x00A0;Overweight (25.0-29.9)</td>
<td align="center" valign="middle">75 (82.4)</td>
</tr>
<tr>
<td align="left" valign="middle">&#x00A0;&#x00A0;&#x00A0;&#x00A0;&#x00A0;Obese (&#x2265;30.0)</td>
<td align="center" valign="middle">16 (17.6)</td>
</tr>
</tbody>
</table>
</table-wrap>
</floats-group>
</article>
